Viking Therapeutics, Inc. (NASDAQ:VKTX) saw a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 11,200,000 shares, a growth of 19.9% from the September 15th total of 9,340,000 shares. Based on an average daily volume of 1,260,000 shares, the days-to-cover ratio is currently 8.9 days. Approximately 17.3% of the shares of the company are sold short.
NASDAQ VKTX opened at $5.90 on Monday. The business’s fifty day simple moving average is $6.18 and its 200-day simple moving average is $6.64. The firm has a market cap of $429.27 million, a PE ratio of -13.41 and a beta of 2.00. Viking Therapeutics has a 52 week low of $3.26 and a 52 week high of $8.87.
Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. As a group, equities research analysts expect that Viking Therapeutics will post -0.61 earnings per share for the current fiscal year.
In other news, major shareholder Ligand Pharmaceuticals Inc sold 164,488 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $8.07, for a total value of $1,327,418.16. Company insiders own 3.70% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. lifted its position in shares of Viking Therapeutics by 592.6% during the 2nd quarter. Goldman Sachs Group Inc. now owns 576,154 shares of the biotechnology company’s stock valued at $4,154,000 after acquiring an additional 492,965 shares during the last quarter. Alliancebernstein L.P. lifted its stake in Viking Therapeutics by 18.9% during the first quarter. Alliancebernstein L.P. now owns 83,600 shares of the biotechnology company’s stock worth $391,000 after purchasing an additional 13,300 shares during the period. Advisor Group Holdings Inc. boosted its holdings in Viking Therapeutics by 39.0% during the second quarter. Advisor Group Holdings Inc. now owns 60,898 shares of the biotechnology company’s stock valued at $439,000 after purchasing an additional 17,077 shares in the last quarter. Royal Bank of Canada grew its stake in shares of Viking Therapeutics by 3.7% in the 1st quarter. Royal Bank of Canada now owns 47,655 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 1,693 shares during the period. Finally, WINTON GROUP Ltd raised its holdings in shares of Viking Therapeutics by 33.7% in the 2nd quarter. WINTON GROUP Ltd now owns 358,101 shares of the biotechnology company’s stock worth $2,582,000 after buying an additional 90,175 shares in the last quarter. 55.30% of the stock is owned by institutional investors and hedge funds.
Before you buy into the 5G hype, you need to see this important presentation. It exposes a shocking 5G lie you’ve been told – and how it could affect your cell phone, and the future of ever cell phone in America.
Several analysts have recently weighed in on VKTX shares. B. Riley reaffirmed a “buy” rating and issued a $15.00 target price on shares of Viking Therapeutics in a report on Thursday, September 10th. William Blair restated a “buy” rating on shares of Viking Therapeutics in a research report on Friday, September 11th. Raymond James reiterated a “buy” rating and set a $25.00 target price on shares of Viking Therapeutics in a research report on Thursday, August 6th. BidaskClub raised Viking Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 10th. Finally, HC Wainwright lifted their price target on Viking Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Friday, August 28th. One equities research analyst has rated the stock with a sell rating and twelve have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $16.33.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis.
See Also: Earnings Per Share (EPS)
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Video games are big business. In 2019, sales of video games were nearly $150 billion worldwide according to the research firm Newzoo. That marked a 7.2% growth from the previous year. And, at the time of the report Newzoo estimated that global video game sales would rise to nearly $160 billion in 2020.
But in the aftermath of the Covid-19 pandemic, things may be changing. The video game industry is undergoing profound changes. Consumers truly have an a la carte model for gaming. Do they want to use a traditional console? They can. How about their laptop? Check. And they can also use their mobile device.
But it’s not just the hardware they use. Multiplayer games are now the rage as is the ability to play online versus other competitors. And then there’s the whole movement towards esports which is helping to inspire a service like Twitch that allows people to watch other people play video games.
As investors, the growth of digital downloads and cloud-based streaming is playing a significant role in the way video game stocks are perceived. And it’s a big reason why many video game stocks are among the best investments at the moment.
In this special presentation, we’ll look at pure-play video game stocks as well as technology companies that are leveraging their strengths to get a share of this growing pie.